Cord blood banking services involve the collection, processing, and storage of stem cells from the umbilical cord blood of newborns. These stem cells have the potential to treat various diseases and conditions, making cord blood banking a valuable resource for future medical treatments.
July 2023: Cell Genesis was ecstatic to share the news that CEXCI Cord Protein Banking was launched. This revolutionary program ushers in a golden age for stem cell research and individualized healthcare. This ground-breaking method uses the protein from umbilical cord stem cells to open up a universe of potential for better health outcomes and game-changing medicinal therapies. The umbilical cord has long been known as a treasure trove of beneficial stem cells, but the advent of cord protein banking signifies a sea change in its use. Nevertheless, new research has shown that the umbilical cord is a treasure trove of valuable proteins with incredible medicinal potential, in addition to being a source of stem cells. Thanks to the innovative methods used in the lab and the cutting-edge technology of Cell Genesis.
May 2023: With a $50 million investment from New York Blood Center, Inc., NYBC Ventures launched its first fund in May 2023 to speed up innovation in areas connected to blood, as well as cellular treatments and supporting technology. Therapeutics, gadgets, and new technologies tackling the most critical issues in infectious illness, transfusion medicine, and benign hematology will be the primary focus of NYBC Ventures, an early-stage life sciences investment firm. Improving patients' lives is another goal of the Fund. It aims to do this by driving strategic partnerships to increase the effect of NYBC and by improving treatments, enabling platforms, and technologies. Breaking new ground in the field of blood and cell-based medicines and technology, this venture fund is the first of its kind.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)